Search research articles
Contact Us
Filters
Showing results (181-190 of 196) with videos related to
Page
of 20
Sort By:
Eclinicalmedicine
|
August 8, 2025
Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study
Anne-Sophie Hamy, Agathe Chabassier, Clara Sebbag, et al.
Lancet (London, England)
|
December 10, 2022
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A Hurvitz, Roberto Hegg, Wei-Pang Chung, et al.
Nature Medicine
|
January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
The New England Journal of Medicine
|
December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
Molecular Cancer
|
August 18, 2023
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron S C Foo, Hiu Y Lam, et al.
Bulletin Du Cancer
|
July 31, 2016
[Breast cancer screening: On our way to the future]
Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, et al.
Nature
|
September 7, 2022
Genomics to select treatment for patients with metastatic breast cancer
Fabrice Andre, Thomas Filleron, Maud Kamal, et al.
Reproductive Biomedicine Online
|
May 7, 2022
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors
Manon Mangiardi-Veltin, Clara Sebbag, Christine Rousset-Jablonski, et al.
Nature Communications
|
June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
Davide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 196) with videos related to
Sort By:
Page
of 20
Eclinicalmedicine
|
August 8, 2025
Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study
Anne-Sophie Hamy, Agathe Chabassier, Clara Sebbag, et al.
Lancet (London, England)
|
December 10, 2022
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A Hurvitz, Roberto Hegg, Wei-Pang Chung, et al.
Nature Medicine
|
January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
The New England Journal of Medicine
|
December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
Molecular Cancer
|
August 18, 2023
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron S C Foo, Hiu Y Lam, et al.
Bulletin Du Cancer
|
July 31, 2016
[Breast cancer screening: On our way to the future]
Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, et al.
Nature
|
September 7, 2022
Genomics to select treatment for patients with metastatic breast cancer
Fabrice Andre, Thomas Filleron, Maud Kamal, et al.
Reproductive Biomedicine Online
|
May 7, 2022
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors
Manon Mangiardi-Veltin, Clara Sebbag, Christine Rousset-Jablonski, et al.
Nature Communications
|
June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
Davide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Page
of 20